SG171601A1 - Further medical uses of antisecretory protein - Google Patents

Further medical uses of antisecretory protein

Info

Publication number: SG171601A1
Authority: SG; Singapore
Prior art keywords: caveolae; dysfunction; lipid rafts; antisecretory protein; receptors
Prior art date: 2006-04-27

Application number

SG201102875-0A

Other languages

English (en)

Inventor

Hans-Arne Hansson

Stefan Lange

Original Assignee

Lantmaennen As Faktor Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-27

Filing date

2007-04-27

Publication date

2011-06-29

2007-04-27 Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab

2011-06-29 Publication of SG171601A1 publication Critical patent/SG171601A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Dispersion Chemistry (AREA)
Neurology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Dermatology (AREA)

SG201102875-0A 2006-04-27 2007-04-27 Further medical uses of antisecretory protein SG171601A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0600933		2006-04-27
US92082607P	2007-03-30	2007-03-30

Publications (1)

Publication Number	Publication Date
SG171601A1 true SG171601A1 (en)	2011-06-29

Family

ID=38655929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201102875-0A SG171601A1 (en)	2006-04-27	2007-04-27	Further medical uses of antisecretory protein

Country Status (19)

Country	Link
US (2)	US8309513B2 (fr)
EP (2)	EP2040734B1 (fr)
JP (2)	JP5323682B2 (fr)
KR (3)	KR101805973B1 (fr)
CN (3)	CN101460187B (fr)
AT (1)	ATE526031T1 (fr)
AU (1)	AU2007244003B2 (fr)
BR (2)	BRPI0710794A2 (fr)
CA (1)	CA2650589C (fr)
DK (3)	DK2037950T3 (fr)
ES (3)	ES2472737T3 (fr)
IL (1)	IL194774A (fr)
MX (1)	MX2008013774A (fr)
NZ (2)	NZ572256A (fr)
PL (2)	PL2363140T3 (fr)
RU (2)	RU2465914C2 (fr)
SG (1)	SG171601A1 (fr)
WO (1)	WO2007126363A2 (fr)
ZA (2)	ZA200809114B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2650132C (fr)	2006-04-27	2017-10-24	Hans-Arne Hansson	Modulation des radeaux lipidiques
KR101805973B1 (ko)	2006-04-27	2017-12-06	란트만넨 아스-팍토르 아베	항분비 단백질의 추가적 의학 용도
CA2650344C (fr)	2006-04-27	2017-10-31	Lantmannen As-Faktor Ab	Nouvelle methode de traitement de l'hypertension intraoculaire
US9220750B2 (en) *	2007-04-27	2015-12-29	Lantmannen As-Faktor Ab	Use of antisecretory factors (AF) for optimizing cellular uptake
US9962424B2 (en)	2007-04-27	2018-05-08	Lantmännen As-Faktor Ab	Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010065342A1 (fr)	2008-11-25	2010-06-10	Temple University	Inhibition par l’angiocidine de la croissance de cellules tumorales
CA2992057C (fr)	2015-07-10	2021-07-20	Lantmannen As-Faktor Ab	Procede de production de jaune d'oeuf ayant une teneur elevee en af-16
KR102268955B1 (ko) *	2016-07-18	2021-06-25	란트만넨 아스-팍토르 아베	항분비 인자 17
WO2020002464A1 (fr)	2018-06-28	2020-01-02	Lantmännen Medical Ab	Facteur antisécrétoire destiné à être utilisé dans le traitement et/ou la prévention d'une insuffisance respiratoire aiguë
CN112770643A (zh)	2018-09-28	2021-05-07	兰特门内保健食品公司	包含麦芽化脱壳燕麦的可消耗产品
CN112770644A (zh)	2018-09-28	2021-05-07	兰特门内保健食品公司	包含麦芽化小麦的可消耗产品
CA3173436A1 (fr)	2020-03-26	2021-09-30	Leif Goransson	Produit consommable comprenant des cereales maltees pour favoriser la recuperation a l'activite physique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH682716A5 (de) *	1992-01-13	1993-11-15	Christian Fricker	Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en)	1994-12-09	1996-12-17	The Reents Of The University Of California	Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) *	1995-08-24	1998-10-19	Rural Patent Svenska Ab	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE506486C2 (sv) *	1996-11-20	1997-12-22	Svenska Lantmaennen Riksfoerbu	Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) *	1998-12-17	2000-09-18	Rural Patent Svenska Ab	NASP-berikad äggula samt dess användning
US7662169B2 (en) *	2000-09-05	2010-02-16	Wittmann Dietmar H	Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en)	2003-09-26	2003-10-29	Melacure Therapeutics Ab	Use of antisecretory factor peptides
CA2650132C (fr)	2006-04-27	2017-10-24	Hans-Arne Hansson	Modulation des radeaux lipidiques
KR101805973B1 (ko)	2006-04-27	2017-12-06	란트만넨 아스-팍토르 아베	항분비 단백질의 추가적 의학 용도
US8329650B2 (en) *	2007-10-19	2012-12-11	Trustees Of Boston University	Method of treating ischemic injury with follistatin-like 1 polypeptide

2007
- 2007-04-27 KR KR1020147032781A patent/KR101805973B1/ko not_active Expired - Fee Related
- 2007-04-27 NZ NZ572256A patent/NZ572256A/en not_active IP Right Cessation
- 2007-04-27 BR BRPI0710794-3A patent/BRPI0710794A2/pt not_active IP Right Cessation
- 2007-04-27 MX MX2008013774A patent/MX2008013774A/es active IP Right Grant
- 2007-04-27 AT AT07748078T patent/ATE526031T1/de not_active IP Right Cessation
- 2007-04-27 ES ES07748080.4T patent/ES2472737T3/es active Active
- 2007-04-27 KR KR1020087029120A patent/KR20090045148A/ko not_active Ceased
- 2007-04-27 CN CN200780014997.4A patent/CN101460187B/zh not_active Expired - Fee Related
- 2007-04-27 NZ NZ572257A patent/NZ572257A/en not_active IP Right Cessation
- 2007-04-27 JP JP2009507631A patent/JP5323682B2/ja active Active
- 2007-04-27 KR KR1020147027241A patent/KR101757523B1/ko active Active
- 2007-04-27 PL PL10188590T patent/PL2363140T3/pl unknown
- 2007-04-27 CN CN201510082714.6A patent/CN104689299B/zh active Active
- 2007-04-27 RU RU2008146734/15A patent/RU2465914C2/ru active
- 2007-04-27 ES ES07748078T patent/ES2374712T3/es active Active
- 2007-04-27 AU AU2007244003A patent/AU2007244003B2/en active Active
- 2007-04-27 DK DK07748080.4T patent/DK2037950T3/da active
- 2007-04-27 WO PCT/SE2007/000413 patent/WO2007126363A2/fr not_active Ceased
- 2007-04-27 DK DK10188590.3T patent/DK2363140T3/en active
- 2007-04-27 CN CN200780014998.9A patent/CN101437533B/zh active Active
- 2007-04-27 CA CA2650589A patent/CA2650589C/fr active Active
- 2007-04-27 RU RU2008146731/15A patent/RU2457853C2/ru active
- 2007-04-27 EP EP07748078A patent/EP2040734B1/fr active Active
- 2007-04-27 DK DK07748078.8T patent/DK2040734T3/da active
- 2007-04-27 BR BRPI0710858-3A patent/BRPI0710858A2/pt not_active Application Discontinuation
- 2007-04-27 PL PL07748078T patent/PL2040734T3/pl unknown
- 2007-04-27 EP EP10188590.3A patent/EP2363140B1/fr active Active
- 2007-04-27 ES ES10188590.3T patent/ES2615515T3/es active Active
- 2007-04-27 SG SG201102875-0A patent/SG171601A1/en unknown
2008
- 2008-10-22 IL IL194774A patent/IL194774A/en active IP Right Grant
- 2008-10-23 ZA ZA200809114A patent/ZA200809114B/xx unknown
- 2008-10-23 ZA ZA200809116A patent/ZA200809116B/xx unknown
- 2008-10-27 US US12/289,389 patent/US8309513B2/en active Active
2010
- 2010-11-02 JP JP2010245989A patent/JP5285043B2/ja active Active
2011
- 2011-02-11 US US13/025,702 patent/US8389468B2/en active Active

Also Published As

Publication number	Publication date
US8309513B2 (en)	2012-11-13
RU2008146731A (ru)	2010-06-10
CN101437533B (zh)	2016-10-12
DK2363140T3 (en)	2017-03-06
KR101805973B1 (ko)	2017-12-06
CA2650589C (fr)	2017-06-13
EP2040734A2 (fr)	2009-04-01
BRPI0710794A2 (pt)	2011-06-21
JP2009535328A (ja)	2009-10-01
ATE526031T1 (de)	2011-10-15
CN101460187A (zh)	2009-06-17
NZ572256A (en)	2012-02-24
AU2007244003B2 (en)	2012-08-02
KR20090045148A (ko)	2009-05-07
DK2040734T3 (da)	2012-01-23
CN104689299A (zh)	2015-06-10
RU2008146734A (ru)	2010-06-10
US8389468B2 (en)	2013-03-05
CN101437533A (zh)	2009-05-20
EP2363140A1 (fr)	2011-09-07
ZA200809114B (en)	2009-06-24
AU2007244003A1 (en)	2007-11-08
MX2008013774A (es)	2009-02-03
KR20140141729A (ko)	2014-12-10
US20090185982A1 (en)	2009-07-23
DK2037950T3 (da)	2014-06-30
JP5323682B2 (ja)	2013-10-23
ES2615515T3 (es)	2017-06-07
JP5285043B2 (ja)	2013-09-11
JP2011032284A (ja)	2011-02-17
KR101757523B1 (ko)	2017-07-12
IL194774A (en)	2015-07-30
WO2007126363A3 (fr)	2008-03-13
EP2040734B1 (fr)	2011-09-28
BRPI0710858A2 (pt)	2011-05-17
KR20140123601A (ko)	2014-10-22
NZ572257A (en)	2011-10-28
HK1131738A1 (en)	2010-02-05
RU2457853C2 (ru)	2012-08-10
RU2465914C2 (ru)	2012-11-10
CA2650589A1 (fr)	2007-11-08
ZA200809116B (en)	2009-07-29
CN101460187B (zh)	2014-11-05
CN104689299B (zh)	2020-02-21
PL2040734T3 (pl)	2012-04-30
ES2472737T3 (es)	2014-07-02
US20110305773A1 (en)	2011-12-15
WO2007126363A2 (fr)	2007-11-08
ES2374712T3 (es)	2012-02-21
PL2363140T3 (pl)	2017-05-31
IL194774A0 (en)	2011-08-01
EP2363140B1 (fr)	2016-12-14
WO2007126363A8 (fr)	2008-10-30

Publication	Publication Date	Title
SG171601A1 (en)	2011-06-29	Further medical uses of antisecretory protein
MX2008013777A (es)	2009-02-03	Usos medicos adicionales de la proteina antisecretora.
WO2010126626A3 (fr)	2010-12-23	Inhibiteurs à mécanisme double pour le traitement de maladie
WO2008042688A3 (fr)	2008-06-12	Inhibiteurs de co-transporteur 2 de sodium glucose et procédés d'utilisation de ceux-ci
WO2008076754A3 (fr)	2008-12-24	Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2010123930A3 (fr)	2011-02-24	Thérapies à base de ligand de récepteur chimiosensible
WO2008050329A3 (fr)	2009-05-07	NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
WO2011041462A3 (fr)	2011-08-11	Composés polycycliques utiles en tant qu'antagonistes du récepteur d'acide lysophosphatidique
WO2008080082A3 (fr)	2008-11-27	Procédés de modulation de set et utilisations associées
WO2011041694A3 (fr)	2011-08-18	Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr)	2011-06-30	Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2009108720A3 (fr)	2009-11-05	Antagonistes des récepteurs d2 de la prostaglandine
WO2010141768A3 (fr)	2011-03-31	Antagonistes polycycliques de récepteurs d'acide lysophosphatidique
WO2010077883A3 (fr)	2010-08-26	Antagonistes des récepteurs d'acide lysophosphatidique
WO2008057802A3 (fr)	2008-11-06	Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
WO2006047516A3 (fr)	2006-10-12	Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2008076392A3 (fr)	2008-08-07	Composés utilisables en tant qu'inhibiteurs de protéines kinases
WO2008054208A3 (fr)	2008-10-16	Utilisation de compositions nutritives pour empêcher des troubles
WO2007106181A3 (fr)	2007-12-06	Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2009050136A3 (fr)	2009-07-02	Procédé de traitement du syndrome de cushing
WO2009145989A3 (fr)	2010-01-21	Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2010042652A3 (fr)	2010-07-29	Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
IL194883A0 (en)	2009-08-03	Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
WO2007120270A3 (fr)	2008-02-28	Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques
WO2010085820A3 (fr)	2010-11-25	Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine